Loading…
← CockpitCompetitor Analysis › DNLI Denali Therapeutics Inc.Open in the cockpit ↗

Denali Therapeutics Inc.DNLICompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops therapies for neurodegenerative diseases using a proprietary blood-brain-barrier delivery platform.

Momentum weak 34
Mkt cap
$2.95B
US dollars, full cap
Free float
94%
of shares outstanding
$/day
$29.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-104.8 pp
WACC 10.4%
Hurdle
n/a
no reverse DCF
Next earnings
103 days
1 Mar 2027
Close · USD$18.40
1D+2.2%
1W-6.7%
1M-2.8%
3M-26.2%
6M-2.3%
YTD+11.4%
1Y+5.9%
ATR %4.8%
Beta1.53
52w lowhigh32.6% off high

What Denali Therapeutics does

Develops therapies for neurodegenerative diseases using a proprietary blood-brain-barrier delivery platform.

Revenue so far has come from partners' upfront and milestone payments rather than product sales, with Takeda and Biogen among those sharing the cost of its drugs; the rest of its funding comes from selling shares to investors.

Products and services

  • Tividenofusp alfa (Hunter syndrome, with Takeda)
  • Pipeline in Alzheimer's and Parkinson's

Customers

  • Neurologists/specialty treatment centers

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Neurodegenerative disease therapeutics

What could go right

  • Hunter syndrome drug commercial launch
  • Pharma partnership milestones with Takeda and Biogen

What could go wrong

  • Neurodegenerative trial failure risk
  • Long development timelines

Moat: narrow (IP / patents, process know-how). Proprietary Transport Vehicle platform for crossing the blood-brain barrier, licensed to major pharma partners.

Headquarters: South San Francisco, California, US · Founded: 2013 · Employees: 503

Named competitors

Denali Therapeutics at a glance

Size Denali Therapeutics (DNLI) is a United States Health Care company (Biotechnology) with a market value of $2.95B, the 1553rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $18.40 on 18 Nov 2026.

Performance Over six months the shares fell 2.3%, against -2.9% for the median peer and -2.2% for the United States market (cap-weighted) — 11th highest of 21 in its peer set.

Growth The operating margin is -2,488.1% (peer median 5.2%).

Valuation It trades at 115.4× enterprise value to sales against a peer median of 6.0× (2nd most expensive of 18).

Capital Return on invested capital runs 104.8 points below its cost of capital (10.4% WACC).

Short interest Short interest is 9.2% of the free float (30 Oct 2026).

Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026Peer median 98DNLI 95
Six months, rebased to 100: Denali Therapeutics against the median of its 20 peers (local-currency closes).

Denali Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$21.4M$0$0$331M$108M
Revenue growth——-100%+205%—
Gross profit$4.58M-$14.8M-$7.79M$314M$101M
EBITDA-$515M-$541M-$494M-$180M-$334M
Net income-$314M-$513M-$423M-$145M-$326M
Free cash flow-$450M-$422M-$364M-$371M-$263M
Capital expenditure$41.8M$9.50M$15.9M$12.9M$17.8M
Total debt$35.2M$42.3M$54.3M$52.2M$60.4M

Quarterly statements and history in the cockpit →

Denali Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-25%0%+25%RUBICONDYNTLXADMA2228BAVAXERS9688VIRP6887028300MBXELVNXNCR688278IOVA300142DNLI6-month return →1-month return →
Up and to the right = strong over both horizons. Denali Therapeutics is the large dot.

Denali Therapeutics competitors and peer comparison

Head to head with its named competitors (DNLI vs BIIB vs LLY vs ALEC)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Denali Therapeutics DNLI$2.95B-2%n/a-2,488%115.4×n/a
Biogen BIIB$37.2B+34%+2%17%4.4×10.1%
Lilly (Eli) LLY$1.30T+36%+46%51%15.6×6.5%
Alector ALEC$383M+21%+151%25%1.5×n/a
Ionis Pharmaceuticals IONS$4.56B-64%-1%-59%5.0×n/a

How Denali Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Denali Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureDNLIPeer medianRank in peer set
1-month return-2.8%-4.6%10th highest of 21
6-month return-2.3%-2.9%11th highest of 21
Distance from 52-week high-32.6%-29.3%10th lowest of 21
Operating margin-2,488.1%5.2%2nd lowest of 18
EV / Sales115.4×6.0×2nd most expensive of 18
ROIC minus cost of capital-104.8 pp-5.7 pp2nd lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%115.4×n/an/a
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%13.2×n/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%3.8×n/an/a
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%6.0×-0.8%+64.6%
XtalPi 2228.HKHong Kong$2.87B-34%+4%-127%21.3×n/an/a
Bavarian Nordic A/S BAVA.CODenmark$2.82B+23%-8%18%2.6×-4.3%+27.4%
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%8.7×29.5%+70.2%
Zai Lab 9688.HKHong Kong$2.79B+23%0%-63%5.4×n/an/a
Virbac VIRP.PAFrance$3.20B-4%+4%15%2.1×5.8%+9.4%
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%5.3×15.8%-1.8%
Sunshine Lake Pharma 6887.HKHong Kong$2.72B-7%+20%-3%5.9×n/an/a
HLB 028300.KSSouth Korea$2.69B-49%+26%-96%38.7×n/an/a
MBX Biosciences MBXUnited States$2.65B+70%n/an/an/an/an/a
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%6,626.2×n/an/a
Xencor XNCRUnited States$2.58B+204%+34%-73%11.7×n/an/a
Xiamen Amoytop Biotech 688278.SSChina$2.56B-27%+18%27%4.3×-0.6%+36.0%
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%8.3×n/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%4.5×2.2%+12.5%
Walvax Biotechnology 300142.SZChina$2.48B-26%-23%5%9.4×29.5%-3.8%

Questions

Who are Denali Therapeutics's main competitors?
Named competitors: Biogen (BIIB), Eli Lilly (LLY), Alector (ALEC), Ionis Pharmaceuticals (IONS). The cockpit's measured peer set (industry) also includes Rubicon Research (RUBICON.NS), Dyne Therapeutics (DYN), Telix Pharmaceuticals (TLX.AX), ADMA Biologics (ADMA), XtalPi (2228.HK), Bavarian Nordic A/S (BAVA.CO).
Is Denali Therapeutics expensive compared with its peers?
On ev / sales it trades at 115.4× against a peer median of 6.0×, 2nd most expensive of 18 in its peer set.
How has Denali Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -2.3% against -2.9% for the median peer; over one year +5.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.